📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
18
TARS Latest News & AI Sentiment Analysis
5 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 8 ARTICLES
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-08-06
Tarsus Pharmaceuticals released its 2026 Q2 earnings presentation on August 6, marking a routine disclosure of financial and operational...
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
Tarsus Pharmaceuticals has announced an acquisition of Alkeus Pharmaceuticals, a consolidation move within the biopharmaceutical sector....
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals (TARS) has secured $125 million in oversubscribed PIPE financing from qualified institutional buyers and...
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Tarsus Pharmaceuticals is acquiring Alkeus Pharmaceuticals to consolidate eye care capabilities and gain access to gildeuretinol...
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching (TARS)
Tarsus Pharmaceuticals (TARS) reported a sequential decline in net product sales during Q1 2026 versus Q4 2025, marking the first...
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
Tarsus Pharmaceuticals (TARS) disclosed an executive leadership transition with Chief Commercial Officer Aziz Mottiwala departing to...
Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc., - M&A Call - Slideshow (NASDAQ:TARS) 2026-07-09
Tarsus Pharmaceuticals (TARS) has announced a material merger or acquisition involving iRenix Medical, signaling strategic portfolio...
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
Tarsus Pharmaceuticals has acquired iRenix Medical and secured a late-stage ophthalmic asset (IRX-101) designed to address vision loss...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice